nextpoint therapeutics

nextpoint therapeutics

We encourage you to review this Privacy Notice often to stay informed of how we may process your information. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Marketing & Sales, Group Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. these pages, please confirm that you are a medical journalist and that you would like to accredit to Higher wind gusts possible.. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Phone: Access to electronic versions of these materials is being made available on this webpage by Bayer in For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Statements, Questions Global, Bayer The final prospectus, when published, will be YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. For the purposes of this provision, the expression an offer to the public in relation to any Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Previous study start-up and clinical monitoring experience desired. Report, Quarterly The securities are only available to, and any invitation, If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Neither this announcement nor anything contained herein shall form the basis of, Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Consensus, Return NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. any jurisdiction. & Stories, Working At the same time, the Group aims to increase its earning power and create value through innovation and growth. Healthy Families, Leaps by Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. R&D expenses before special items amounted to 5.3 billion euros. There will be no public One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. Water 4. Team, Our Sustainable Beef Production, Responsible Business Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Board, Document Download We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Portal, Countermotions NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Neither this announcement nor anything contained If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Republic, Dominican Agriculture, Recognize & At the same time, the Group aims to increase its earning power and create value through innovation and growth. Republic of, New Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. For more information. Bayer Global NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. Regulations, Sustainable Safety, Science Insect Decline, Raising Nutrition . Prospectus Directive), as permitted under the Prospectus Directive, or. Responsible Care, Bayer We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Tool, Innovation As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Council, Stakeholder Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). Drs. Archive, Events The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Career, Your Menu, Our INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. The investment portfolio includes more than 50 companies. of NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Scientists, At If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Kaiser-Wilhelm-Allee 1 NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Announcements, Sustainability & Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Get the latest business insights from Dun & Bradstreet. Phone: +49 30 468 1111, Alfred-Nobel-Str. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the for Prescription Medicine in Europe, Counterfeits in 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Investing in a stronger future - for our shareholders, and for the world. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Compact, Group Bayer Global Information, Recognizing Winds SE at 15 to 25 mph. The following materials are not directed at or to be accessed by persons located in the United Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. Sci Immunol. 2021 Jul 9;6(61):9792. For more information, go to. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent sufficient information on the terms of the offer and any securities to be offered so as to enable an An investment decision regarding the securities referred to herein should only application, Your requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. life. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Report, More Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Bachelor of Science required, Masters of Science preferred. The Bayer brand stands for trust, reliability and quality throughout the world. Making press Prospectus Directive. +49 214 30 1, Mllerstrae 178 Cancer Immunol Res. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Our team of . Drs. on We provide these links merely for your convenience. any facility of a national securities exchange of the United States and the tender offer cannot be Our innovative approach integrates foundational. Kingdom, Contact Trends, Rise You can use the Easy Apply feature on LinkedIn view job description. & Medical Devices, Crop Bayer is an innovation company with a more than 150-year history. Bayers leadership in agriculture provides tailored solutions Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Learn more about Bayer and the opportunities available. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Lanka, Taiwan, By clicking on the I AGREE button, I certify that I am not located Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Related Persons. Slavery Act Statement, Position Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Furthermore, where permissible, we may charge for this service. in any other circumstances falling within Article 3(2) of the Prospectus Directive. The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. indirectly, in or into the United States by use of the mails or by any means or instrumentality KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. I am currently pursuing a M.Sc. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? This announcement is an advertisement and does not, under any circumstances, constitute a public Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. good faith and for information purposes only. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. We will never disclose your PII to third parties for direct marketing purposes without your authorization. Updates, Management & Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. We are currently looking to add an Associate Director or Director . 50 CAMBRIDGE, Mass. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. and Life in balance, Healthy The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. | Learn more about Anne Koehler, PhD's . This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. & Solutions, Development Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site.

What Is Uscis Lee's Summit Production Facility, Washington Middle School Shooting, Cheap Houses For Sale In West Melbourne Florida, Articles N